

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7573494
<b>Application Number:</b>	10821930
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3681
<b>Title of Invention:</b>	Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
<b>First Named Inventor/Applicant Name:</b>	Dario Neri
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Cynthia Cervoni
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	ELLIS-0002-P02-C01
<b>Receipt Date:</b>	07-MAY-2010
<b>Filing Date:</b>	12-APR-2004
<b>Time Stamp:</b>	16:27:12
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	Alberts-CellsCanBe.pdf	228910 d429bd35fc7281340360f5dea7e625ee3df 8272	no	2

### Warnings:

### Information:

2	NPL Documents	Argraves-AminoAcids.pdf	1261037 1ba169835c4c15ee4b86396bb7e9e37822 beb5a0	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Batista-TheTwoMembranes.pdf	1101179 6d6cdf339030ff9919b927b2530b5213b80 08d22	no	10
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Bauters-Accumulation.pdf	1092053 6f91200fda2f1f780da3f1dea98140723bf6b 689	no	13
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Berndorff-ImagingofTumor.pdf	211634 33f33f9b45d518af1892e50fe4c81a8fbcc68e e08	no	10
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Berndorff- Raidoimmunotherapy.pdf	420825 499b6d9a3ae58df4e86fdb072a690843b1 1f480	no	11
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Bestagno- MembraneImmunoglobulins. pdf	807633 a846059d226fd03c8d50ce666e42a19b671 1c9f	no	7
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Blythe-Benchmarking.pdf	3232443 5dae9c60189294ee4de3f49a023d272656b ed8a1	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Caldas-Humanizationofanti- CD18.pdf	848826 bd397a91fb53fea0ca0ceee5c08d945ae8e e103	no	12
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Casset-APeptideMimetic.pdf	687314 a21eb0850b8306b96a43a6ea32090b9ce60 3fa6a	no	8
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	Castellani-TheFibronectinIsoform-1.pdf	1741905 571851275784865b649056d87ab42c8271 e51d86	no	8
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Chen-AdhesionMediated.pdf	5345 7917450c158b340d07f00823ee11b540dcf c0714	no	2
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Chien-SignificantStructural.pdf	1359826 633e3277bc2d7dcea60d6933b263b3da3b 56bea3	no	5
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Chirivi-Abstract14.pdf	176673 e88e6093da1e9c101237d9aa283681d6b0e a2dfb	no	1
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Colman-EffectsofAminoAcid.pdf	366756 f595e37f38d6f04d13c09bcc53f3049e972c9 1ad	no	4
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Dinkelborg-MolecularImaging.pdf	948676 7f4af2ce76a528ce966da4b2c6f509fe6601 7e0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Epstein-FDARegulation.pdf	680572 5a64bb87b5b4489090d42986d769ae9792 8809db	no	8
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Ffrench-Constant.pdf	1185260 16487994afa120e90085edfec8bd1b95c15 0e90d	no	14
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Freshney-CultureofAnimalCells.pdf	815861 059e3eaa88b00ea2228d7654757436152f 61e0a	no	7
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	Garcia-Velasco-Regulation.pdf	186939 4a562b64182709e351d95eadac8ab3c2e57 b4ea9	no	5
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	George-RadiometalLabeling.pdf	515892 7caa5c6918be04d0a587eb9990539aea113 63697	no	6
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Giusti-SomaticDiversification.pdf	1068895 e44747fc7154f87a524eb5a6151584f6fb69 e563	no	5
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Glukhova-ExpressionofFibronectin.pdf	1302016 fbef933dbe5f0aea3f6b72e32c85c4092931 309e	no	10
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Goel-99mTc.pdf	391042 f25344e44955add3d8f1fbdf86f31a6d8742 cc0e	no	9
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Greenspan-DefiningEpitopes.pdf	2980023 5a5e8c4dbea2e1de0b07fb198e98df442ed c24eb	no	2
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Gussow-HumanizationofMonoclonalAntibodies.pdf	805878 f50a4ee07a95c1f4d8b86810d0db1c54bae ec978	no	23
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Halin-antibody-based-CancerResearch.pdf	4280345 9bcc74c7321c93a2e3c5d7d2884a842590b 8c95a	no	4
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Hashimoto-Uoshima-AlternativelySpliced.pdf	1322988 44bf58e3f4453736c286858c2c63aff2fd52f abf	no	10
<b>Warnings:</b>					
<b>Information:</b>					

29	NPL Documents	Holm-FunctionalMapping.pdf	1098744 3a80bad43d5c1214de70c54fa1419125fd2 476fc	no	10
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Isemura- IsolationandCharacterization. pdf	359930 2e7575f/5a5aa32a0710692f43dc5ba67f64 6ba9	no	4
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Kaspar-FibronectinAsTarget.pdf	355026 89f1d09c1e4f7fb8b8eb6a29f4f1fa32d2dd2 eb4	no	9
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Katugampola.pdf	178176 4c0f5587fef741ce5dea5c01c255b476c82a 437e	no	6
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	Kern-InteractionofTypeIV.pdf	907854 a660431fe39baac33def2f1fadac1f77565c3 1f2	no	9
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	Kim.pdf	1734966 f606c00e196db3cd95b29de42709825aecdf d82d	no	10
<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	Kogan-ASingleAminoAcid.pdf	14588632 41651840227a701367ed78d9974b8bbd9 878c80	no	9
<b>Warnings:</b>					
<b>Information:</b>					
36	NPL Documents	Korver-Measurement.pdf	569965 8ebd669884a9d1a6b87420518b7e39df72e 44faa	no	6
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	LI-MammalianCell.pdf	818412 eaad9347ebceab2baa7c5f6c4a1290c38fbdb 115f	no	6
<b>Warnings:</b>					
<b>Information:</b>					

38	NPL Documents	Liu-TreatmentofBCellLymphoma.pdf	1241977 87ed50f066047d88adfd5446ec7aa55ed8 0dcda	no	10
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	MacCallum-AntibodyAntigen.pdf	1367106 5fbe7b813ba41f6aa175781fe6572fd77e0f 554	no	14
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	Magnusson-Fibronectin.pdf	793473 287a48a4c3ae0222c4bc8daa37735b1799d b1891	no	8
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	Mariuzza-TheStructuralBasis.pdf	1467825 e7a67236a86c418fc70e41d5a079e34515ae 27a5	no	22
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	Marty-Production.pdf	1119777 c0bed70bd319c31a31562b3ebd4114a19b 497c1a	no	9
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	Matsuura-AnAlphaNAcetyl.pdf	507550 7f9efefb298d6e1ce100fdb98e57f6bfd1dce 01d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	Matsuura-OncofetalDomain.pdf	545037 e3a9ae8e25292067b9dcaab0f07415ff0495 f12d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	Menrad-ExpertOpinion1.pdf	1382226 c1d9d7854afaa578d244e9b21883574a06a 5f02a	no	10
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	Morikawa-RADIOIMMUNOASSAY.pdf	413893 2a87b004da578bac76ea9476fea2e266f089 4dad	no	8
<b>Warnings:</b>					
<b>Information:</b>					

47	NPL Documents	Ngo- ComputationalComplexity.pdf	4588213 1735f4313092783f9e24e204e75cd65f4f7bf fb7	no	38
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	Nozawa-HMMC-1.pdf	735334 f306bb0bcce9be810878c5d8d6edbbe1c58 b5a39	no	8
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	Orlova- ComparativeBiodistribution.pdf	887432 50db8a1ee7efd51705ed86b6d430900493f a9f7b	no	12
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	Pascalis-Grafting.pdf	995707 eb589e7bbfb5245fee2e2f72960b51910d8 086d6	no	10
<b>Warnings:</b>					
<b>Information:</b>					
51	NPL Documents	Pasqualini-AlphaVIntegrins.pdf	1221501 485631e0c18d929e6b1cbe1054bbedc581 80fbd	no	6
<b>Warnings:</b>					
<b>Information:</b>					
52	NPL Documents	Poon-LaserInducedAbstract.pdf	90930 507e4dac3b28c8090d2fd3eb0619004573a 911fe	no	2
<b>Warnings:</b>					
<b>Information:</b>					
53	NPL Documents	Rudikoff-SingleAminoAcid.pdf	942238 f0dff4b501d112101c2d872e6a2b99abcb5 baff	no	5
<b>Warnings:</b>					
<b>Information:</b>					
54	NPL Documents	Schier- IsolationofPicomolarAffinity. pdf	1637706 86ff43fb8ff4fd24df95f8e63fbcd9b07bf37 3a	no	17
<b>Warnings:</b>					
<b>Information:</b>					
55	NPL Documents	Swiss-Prot-A2KBB9.pdf	37296 03a4d0ca778e000f68bf05bfa6aa38799274 123d	no	1
<b>Warnings:</b>					
<b>Information:</b>					

56	NPL Documents	Swiss-Prot-A2KBC0.pdf	50456 355aad9350e237825554f869b854656bda2 fd5c4	no	1
----	---------------	-----------------------	---	----	---

**Warnings:**

**Information:**

57	NPL Documents	Swiss-Prot-A2KBC1.pdf	51579 346c048e471b8d0a97256ae6f5d0a9e7a6d 29178	no	1
----	---------------	-----------------------	---	----	---

**Warnings:**

**Information:**

58	NPL Documents	Swiss-Prot-A2KBC2.pdf	51665 105d59a8755f250bc9a8832d9be06bf9ca5 e7ef8	no	1
----	---------------	-----------------------	---	----	---

**Warnings:**

**Information:**

59	NPL Documents	Swiss-Prot-A2KBC3.pdf	50647 e971e407338ed9d8bf6b60fb6934f5267aee abaf	no	1
----	---------------	-----------------------	---	----	---

**Warnings:**

**Information:**

60	NPL Documents	Tait-DevelandCharac.pdf	909524 718adf896c012343f097191e329c7108cfaf3 963	no	9
----	---------------	-------------------------	--	----	---

**Warnings:**

**Information:**

**Total Files Size (in bytes):** 71727543

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.